Department of Endocrinology and Nutrition, Endocrinology and Nutrition Research Center, School of Medicine, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain.
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8472-8479. doi: 10.26355/eurrev_201812_16547.
A common G-to-A transition (rs670) of the Apoprotein subtype 1 APOA1 gene has been evaluated. The presence of the A allele has been related with increased activity. We investigated the role of this genetic variant (rs670) on lipoprotein levels and anthropometric parameters after biliopancreatic diversion (BPD) surgery in morbid obese patients.
Sixty-three patients with morbid obesity without diabetes mellitus type 2 were enrolled. Biochemical and anthropometric evaluation were registered before and after one, two and three years follow-up.
Genotype distribution was 73% (n=46) GG, 25.6% (n=16) GA and 1.4% (n=1) AA for the rs670 polymorphism. Percent excess weight loss, anthropometric and biochemical parameters improved in both groups (GG vs. GA±AA). The decrease of fasting insulin levels at 1 years (delta: -3.7±1.4 mUI/L vs. -2.9±1.2 mUI/L; p=0.02), 2 years (delta: -4.8±0.3 mUI/L vs. -4.0±0.2 mUI/L; p=0.01) and 3 years (delta: -6.7±3.1 mUI/L vs. -3.9±2.1 mUI/L; p=0.03) was higher in A allele carriers than in non carriers. The improvement of HOMA-IR levels at 1 years (delta: -3.7±1.4 mUI/L vs. -2.9±1.2 mUI/L; p=0.02), 2 years (delta: -4.8±0.3 mUI/L vs. -4.0±0.2 mUI/L; p=0.01) and 3 years (delta: -6.7±3.1 mUI/L vs. -3.9±2.1 mUI/L; p=0.03) was also higher in A allele carriers than non-carriers. Finally, the increase of HDL-cholesterol levels at 1 years (delta: 2.2±0.6 mg/dl vs. -1.2±0.2 mg/dl; p=0.001), 2 years (delta: 2.5±0.4 mg/dl vs. 0.3±0.1 mg/dl; p=0.01) and 3 years (delta: 2.4±0.6 mg/dl vs. 0.4±2.3 mg/dl; p=0.02) was higher in A allele carriers than non-carriers.
This variant of the APOA1 gene showed important effects on HDL-cholesterol, HOMA-IR and insulin resistance after DBP for 3 years.
评估载脂蛋白亚型 1 APOA1 基因的常见 G 到 A 转换(rs670)。存在 A 等位基因与活性增加有关。我们研究了这种遗传变异(rs670)在肥胖症患者接受胆胰分流术(BPD)后的脂蛋白水平和人体测量参数中的作用。
招募了 63 名无 2 型糖尿病的病态肥胖患者。登记了生化和人体测量评估,随访 1、2 和 3 年。
rs670 多态性的基因型分布为 73%(n=46)GG、25.6%(n=16)GA 和 1.4%(n=1)AA。两组(GG 与 GA±AA)的体重减轻百分比、人体测量和生化参数均有所改善。1 年时空腹胰岛素水平下降(差值:-3.7±1.4 mUI/L 与-2.9±1.2 mUI/L;p=0.02)、2 年时(差值:-4.8±0.3 mUI/L 与-4.0±0.2 mUI/L;p=0.01)和 3 年时(差值:-6.7±3.1 mUI/L 与-3.9±2.1 mUI/L;p=0.03)在 A 等位基因携带者中更高。1 年时 HOMA-IR 水平改善(差值:-3.7±1.4 mUI/L 与-2.9±1.2 mUI/L;p=0.02)、2 年时(差值:-4.8±0.3 mUI/L 与-4.0±0.2 mUI/L;p=0.01)和 3 年时(差值:-6.7±3.1 mUI/L 与-3.9±2.1 mUI/L;p=0.03)在 A 等位基因携带者中也更高。最后,1 年时 HDL-胆固醇水平升高(差值:2.2±0.6 mg/dl 与-1.2±0.2 mg/dl;p=0.001)、2 年时(差值:2.5±0.4 mg/dl 与 0.3±0.1 mg/dl;p=0.01)和 3 年时(差值:2.4±0.6 mg/dl 与 0.4±2.3 mg/dl;p=0.02)在 A 等位基因携带者中也更高。
这种 APOA1 基因的变体在 DBP 后 3 年内对 HDL-胆固醇、HOMA-IR 和胰岛素抵抗有重要影响。